The European Medicines Agency (EMA) is investigating reports of AstraZeneca’s Covid-19 vaccine causing Guillain-Barre syndrome, as the pharmaceutical company remains embroiled in controversy over the jab’s link to blood clotting.

In a meeting this week, the European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) revealed that it was “assessing reports” of the rare immune system disorder being found in people following vaccination.

“As part of the review of the regular pandemic summary safety reports for Vaxzevria, AstraZeneca’s Covid-19 vaccine, the PRAC is analysing data provided by the marketing authorization holder on cases of Guillain-Barre syndrome (GBS) reported following vaccination”, the PRAC declared. (RT)